A Hidden Viral Threat: Reactivation Risk in Patients on Common Biologics
A new meta-analysis provides critical data on the risk of hepatitis B virus (HBV) reactivation in patients with a specific immune profile—those who are HBsAg-negative but anti-HBc-positive—undergoing treatment with tumor necrosis factor-alpha (TNF-α) inhibitors. These biologic drugs are widely used for immune-mediated inflammatory diseases. The study, synthesizing data from 13 cohorts involving nearly 1,500 patients, found the overall pooled incidence of reactivation to be a low 2.3%. Crucially, the analysis revealed that the potency of the TNF-α inhibitor did not significantly alter this risk, with high-potency and low-potency agents showing comparable reactivation rates. The most significant predictor of increased risk was the absence of protective anti-HBs antibodies, which more than doubled the likelihood of reactivation.
Why it might matter to you: This research directly informs infection control and antiviral prophylaxis strategies for a large patient population on immunosuppressive therapy. For clinicians managing infectious disease risks, it clarifies that the choice of TNF-α inhibitor based on potency alone may not be a key factor in HBV reactivation risk stratification. The findings underscore the paramount importance of thorough serological screening, particularly assessing anti-HBs status, to identify the subset of patients who require heightened surveillance or preemptive antiviral therapy, thereby preventing a serious complication of treatment.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
